Dr. Kalliwoda Research GmbH

Marinomed Biotech AG: Kauf Empfehlung

Marinomed Biotech AG Analyse-Zusammenfassung, Summary:

Marinomed focuses on revitalizing sales in the Virology segment and overcoming challenges in the Immunology segment to drive growth.

Despite a decrease in revenues in 2023 (EUR 9.18 million) compared to 2022 (EUR 11.28 million), attributed to reduced demand and partner inventories, Marinomed saw an increase in other income.

Marinomed's total assets decreased from EUR 22.29 million in 2022 to EUR 14.61 million in 2023, primarily driven by reduced current assets.

Marinomed aims to achieve operating profitability through strategic partnerships across segments. It focuses on expanding the Carragelose business and concluding further license agreements for Budesolv.

Marinomed bolstered its business development team in 2023, prioritizing professionals with pharmaceutical industry expertise.

Based on our DCF model, we stick to the determined a fair value of EUR 55.53 and a price target of EUR 63.02.



Dr. Norbert Kalliwoda, geschäftsführender Gesellschafter, Managing Owner, Dipl.-Kfm., Dipl.-Hdl. CEFA-Analyst (Certified European Financial Analyst, DVFA), 60325 Frankfurt Westend und 64839 Münster bei Darmstadt

Die vollständige Analyse können Sie hier downloaden